Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca : India regulators probe alleged AstraZeneca shot reaction, trial continues

11/29/2020 | 12:10pm EST
FILE PHOTO: A test tube labelled with the vaccine is seen in front of AstraZeneca logo in this illustration taken

NEW DELHI/MUMBAI (Reuters) - The Indian Council of Medical Research (ICMR) is assisting an inquiry into an alleged adverse reaction during AstraZeneca's COVID-19 vaccine trial, but has found no reason to recommend halting it, a senior official at the regulator said on Sunday.

A 40-year-old man said in a complaint seen by Reuters that he had suffered serious "neurological and psychological" symptoms after receiving the vaccine in a trial being run by the British drugmaker's partner Serum Institute of India (SII).

"There was no immediate cause of concern at this stage," Samiran Panda, head of Epidemiology and Communicable Diseases at the ICMR, the research body involved in trials, told Reuters.

"It doesn't mean that long term assessment will not happen, it is still happening. I am aware of the activity," Panda said.

AstraZeneca did not respond to a request for comment.

Law firm N.G.R. Prasad & R. Rajaram Advocates sent the complaint by the unnamed volunteer, who is seeking 50 million rupees ($676,288) in compensation and a suspension of testing, manufacturing and distribution of the vaccine, to ICMR, SII, AstraZeneca and the Drugs Controller General of India.

"While the Serum Institute of India is sympathetic with the volunteer's medical condition, there's absolutely no correlation with the vaccine trial," SII said.

"(The) volunteer was specifically informed by the medical team that the complications he suffered were independent of the vaccine trial he underwent," it added.

The Drugs Controller General of India, who is responsible for drug and vaccine approval, could not immediately be reached for comment on Sunday.

(Reporting by Manoj Kumar and Euan Rocha; Editing by Alexander Smith)

By Manoj Kumar and Euan Rocha


© Reuters 2020
All news about ASTRAZENECA PLC
02:23pASTRAZENECA : Brazil's health agency approves the use of two vaccines
AQ
02:10pASTRAZENECA : Brazil Starts Its Covid-19 Vaccine Rollout -- 3rd Update
DJ
01:52pASTRAZENECA : Brazil Authorizes Use of Two Covid-19 Vaccines -- Update
DJ
01:39pBrazil Authorizes Use of Two Covid-19 Vaccines
DJ
01:28pASTRAZENECA : Brazil clears emergency use of Sinovac, AstraZeneca vaccines, shot..
RE
10:07aASTRAZENECA : Brazil regulator to decide on emergency use of Sinovac, AstraZenec..
RE
03:55aSwiss to get Moderna vaccine in tranches until mid-year - Blick
RE
01:32aTHE LATEST : Pakistan approves Oxford-AstraZeneca vaccine
AQ
01/16THE LATEST : Biden elevates science adviser to Cabinet level
AQ
01/16ASTRAZENECA : India starts world's largest COVID-19 vaccination drive
AQ
More news
Financials (USD)
Sales 2020 26 400 M - -
Net income 2020 2 992 M - -
Net Debt 2020 13 217 M - -
P/E ratio 2020 43,0x
Yield 2020 2,73%
Capitalization 135 B 135 B -
EV / Sales 2020 5,63x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 126,21 $
Last Close Price 103,14 $
Spread / Highest target 51,3%
Spread / Average Target 22,4%
Spread / Lowest Target -18,5%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC3.66%135 464
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993